SCHEMBL2861586

SCHEMBL2861586

O=C(O)c1cc(F)c2[nH]nc(-c3cccc(F)c3)c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 5/20 0.56
MAPK1 P28482 2/20 0.48
MAPK6 Q16659 2/20 0.48
MAPKAPK3 Q16644 1/20 0.48
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
PIN1 Q13526 1/20 0.41
PTGFR P43088 1/20 0.41
HTR7 P34969 1/20 0.40
AXL P30530 1/20 0.40
KMO O15229 2/20 0.40
GRK6 P43250 1/20 0.40
KDM4C Q9H3R0 2/20 0.39
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
NR4A1 P22736 1/20 0.39
NR4A2 P43354 1/20 0.39
NR4A3 Q92570 1/20 0.39
NOTUM Q6P988 1/20 0.39
XPO1 O14980 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2862110 0.88 MAP2K4 (0.55) MAP2K4MAPK1MAPK6MAPKAPK3CSNK2A2
SCHEMBL2861181 0.84 MAP2K4 (0.51) MAP2K4MAPK1MAPK6MAPKAPK3CSNK2A2
SCHEMBL2861275 0.82 CA12 (0.50) MAP2K4MAPK1MAPK6MAPKAPK3NOTUM
SCHEMBL2865663 0.81 DYRK1A (0.48) MAP2K4
SCHEMBL4334123 0.81 ROCK2 (0.43) MAP2K4MAPK1
SCHEMBL2858476 0.80 MAP2K4 (0.68) MAP2K4MAPK1MAPK6MAPKAPK3CSNK2A2
SCHEMBL4334510 0.79 MAPK1 (0.39) MAP2K4MAPK1XPO1
SCHEMBL2866665 0.79 GABRA5 (0.48)
SCHEMBL4338629 0.79 MAPK1 (0.55) MAPK1
SCHEMBL2858316 0.78 MAP2K4 (0.52) MAP2K4MAPK1MAPK6MAPKAPK3PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAP2K4 61/4885MAPK1 1/4885MAPK6 24/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 MAP2K4 53/4885MAPK1 1/4885MAPK6 5/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAP2K4 61/4885MAPK1 1/4885MAPK6 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.